Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H1 2019
Summary
According to the recently published report Toll Like Receptor 4 - Pipeline Review, H1 2019; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 37 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
The report Toll Like Receptor 4 - Pipeline Review, H1 2019 outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Atherosclerosis, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Pain, Rheumatoid Arthritis, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Chronic Liver Disease, Complicated Intra-Abdominal Infections, Crohns Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatic Injury, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rosacea, Soft Tissue Sarcoma and Xerostomia.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Summary
According to the recently published report Toll Like Receptor 4 - Pipeline Review, H1 2019; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 37 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
The report Toll Like Receptor 4 - Pipeline Review, H1 2019 outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Inflammation, Atherosclerosis, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Pain, Rheumatoid Arthritis, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Chronic Liver Disease, Complicated Intra-Abdominal Infections, Crohns Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatic Injury, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rosacea, Soft Tissue Sarcoma and Xerostomia.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
TABLE OF CONTENTS
Introduction
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Appendix
List Of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1)
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AptaTargets SL, H1 2019
Pipeline by Batu Biologics Inc, H1 2019
Pipeline by Cyxone AB, H1 2019
Pipeline by Eisai Co Ltd, H1 2019
Pipeline by eTheRNA Immunotherapies NV, H1 2019
Pipeline by EyeGene Inc, H1 2019
Pipeline by GigaGen Inc, H1 2019
Pipeline by GlaxoSmithKline Plc, H1 2019
Pipeline by Harbor Therapeutics Inc, H1 2019
Pipeline by Immune Design Corp, H1 2019
Pipeline by Immunovo BV, H1 2019
Pipeline by NovImmune SA, H1 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Pipeline by Vascular Biogenics Ltd, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019
List Of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
RELATED REPORTS
Toll Brothers Full Year Operating Financial
Toll Brothers 2023 Full Year Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Real Estate Industry This report is part of the
View ReportToll Like Receptor 9 (CD289 or TLR9) - Drugs in Development, 2021
Toll Like Receptor 9 (CD289 or TLR9) - Drugs in Development, 2021Toll Like Receptor 9 (CD289 or TLR9) - Drugs in Development, 2021 provides in depth analysis on Toll Like
View ReportToll Like Receptor 9 (CD289 or TLR9) - Drugs in Development, 2021
Toll Like Receptor 9 (CD289 or TLR9) - Drugs in Development, 2021Toll Like Receptor 9 (CD289 or TLR9) - Drugs in Development, 2021 provides in depth analysis on Toll Like
View ReportCells Expressing C Type Lectin Domain Family 12 Member A (Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic Cell Associated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A) - Drugs in Development, 2021
Cells Expressing C Type Lectin Domain Family 12 Member A (Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic Cell Associated Lectin 2 or C Type Lectin Like Molecule 1
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
